论文部分内容阅读
目的观察硫酸镁联合利托君治疗早产胎膜早破(PROM)的临床疗效。方法选择医院产科2016年1-12月收治的早产PROM孕妇80例,采用双盲法随机分为2组,每组40例。对照组给予硫酸镁治疗,观察组在对照组基础上给予利托君治疗,比较2组临床效果。结果观察组孕期延长时间、抑制宫缩起效时间、新生儿Apgar评分、新生儿体质量均优于对照组,差异均有统计学意义(P<0.05)。观察组产后出血发生率低于对照组,差异有统计学意义(P<0.05);2组分娩方式比较差异无统计学意义(P>0.05)。观察组并发症发生率为2.5%低于对照组的20.0%,差异有统计学意义(χ2=9.263,P<0.05)。结论硫酸镁联合利托君治疗早产PROM临床效果较好,有临床推广价值。
Objective To observe the clinical efficacy of magnesium sulfate combined with Rituximab in the treatment of premature rupture of membranes (PROM). Methods Eighty pregnant women with PROM in preterm delivery from January 2016 to January 2016 were selected and randomly divided into two groups (40 cases in each group) by double-blind method. The control group was treated with magnesium sulfate. The observation group was treated with ritodrine on the basis of the control group, and the clinical effects were compared between the two groups. Results The prolongation of pregnancy time, inhibition of contractile onset time, neonatal Apgar score and neonatal body weight in the observation group were all better than those in the control group, with statistical significance (P <0.05). The incidence of postpartum hemorrhage in the observation group was lower than that in the control group, with statistical significance (P <0.05). There was no significant difference in the delivery mode between the two groups (P> 0.05). The incidence of complication in the observation group was 2.5% lower than that in the control group (20.0%), the difference was statistically significant (χ2 = 9.263, P <0.05). Conclusion Magnesium sulfate combined with Rituximab treatment of preterm PROM clinical effect is better, clinical value.